Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10911-012-9268-y.

Title:
Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer | Journal of Mammary Gland Biology and Neoplasia
Description:
The insulin and insulin like growth factor (IGF) signaling systems are implicated in breast cancer biology. Thus, disrupting IGF/insulin signaling has been shown to have promise in a number of preclinical models. However, human clinical trials have been less promising. Despite evidence of some activity in early phase trials, randomized phase III studies have thus far been unable to show a benefit of blocking IGF signaling in combination with conventional strategies. In breast cancer, combination anti IGF/insulin signaling agents with hormone therapy has not yet proven to have benefit. This inability to translate the preclinical findings into useful clinical strategies calls attention to the need for a deeper understanding of this complex pathway. Development of predictive biomarkers and optimal inhibitory strategies of the IGF/insulin system should yield better clinical strategies. Furthermore, unraveling the interaction between the IGF/insulin pathway and other critical signaling pathways in breast cancer biology, namely estrogen receptor-α (ERα) and epidermal growth factor receptor (EGFR) pathways, provides additional new concepts in designing combination therapies. In this review, we will briefly summarize the current strategies targeting the IGF/insulin system, discuss the possible reasons of success or failure of the existing therapies, and provide potential future directions for research and clinical trials.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, google, scholar, cas, pubmed, growth, breast, receptor, insulinlike, factor, res, human, cells, insulin, signaling, yee, igf, cell, clin, mol, canc, biol, type, article, zhang, antibody, inhibitor, activity, phase, estrogen, tumor, targeting, clinical, therapy, pathway, resistance, oncol, expression, inhibits, lee, akt, doiccr, ther, mammary, yang, hormone, treatment, trastuzumab, patients, sachdev,

Topics {✒️}

pi3k/mtor inhibitors nvp-bez235 phosphatidylinositol 3-kinase/akt-mediated activation igf-ir-induced mammary tumors alpha6beta4 integrin-dependent activation month download article/chapter node-negative breast cancer growth factor signalling growth factor-1r/ir igf-1r antibody dalotozumab igf-1r monoclonal antibody kinase-deficient igf-i her2-positive breast cancer igf-1r-dependent mechanism anti-igf-ir therapy hormone receptor-positive hormone-receptor positive estrogen-dependent breast cancer high igf-ir activity tyrosine kinase inhibition trastuzumab-resistant breast cancer epidermal growth factor insulin/igf-1 hybrid receptors breast cancer biomarkers small-cell lung cancer disrupting igf/insulin signaling vivo anti-tumour activity wild type igf-i growth factor receptor igf-ir kinase predictive biomarkers receptor/her2 inhibitor related subjects growth factor ii growth factor-ii growth factor signaling insulin receptor substrate-2 insulin receptor substrate-1 primary tumor growth plasma c-peptide small molecule inhibitor blocking igf signaling privacy choices/manage cookies humanised monoclonal antibody mesenchymal transition mediated postmenopausal breast cancer human cancer therapy human breast cancer receptor saturation mechanism human cancer cells refractory solid tumors

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer
         description:The insulin and insulin like growth factor (IGF) signaling systems are implicated in breast cancer biology. Thus, disrupting IGF/insulin signaling has been shown to have promise in a number of preclinical models. However, human clinical trials have been less promising. Despite evidence of some activity in early phase trials, randomized phase III studies have thus far been unable to show a benefit of blocking IGF signaling in combination with conventional strategies. In breast cancer, combination anti IGF/insulin signaling agents with hormone therapy has not yet proven to have benefit. This inability to translate the preclinical findings into useful clinical strategies calls attention to the need for a deeper understanding of this complex pathway. Development of predictive biomarkers and optimal inhibitory strategies of the IGF/insulin system should yield better clinical strategies. Furthermore, unraveling the interaction between the IGF/insulin pathway and other critical signaling pathways in breast cancer biology, namely estrogen receptor-α (ERα) and epidermal growth factor receptor (EGFR) pathways, provides additional new concepts in designing combination therapies. In this review, we will briefly summarize the current strategies targeting the IGF/insulin system, discuss the possible reasons of success or failure of the existing therapies, and provide potential future directions for research and clinical trials.
         datePublished:2012-10-10T00:00:00Z
         dateModified:2012-10-10T00:00:00Z
         pageStart:251
         pageEnd:261
         sameAs:https://doi.org/10.1007/s10911-012-9268-y
         keywords:
            Breast cancer
            Insulin-like growth factor
            Type I receptor IGF receptor
            Insulin receptor
            Predictive biomarkers
            Oncology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10911-012-9268-y/MediaObjects/10911_2012_9268_Fig1_HTML.gif
         isPartOf:
            name:Journal of Mammary Gland Biology and Neoplasia
            issn:
               1573-7039
               1083-3021
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yuzhe Yang
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Minnesota
                     address:
                        name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas Yee
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Department of Medicine, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Minnesota
                     address:
                        name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer
      description:The insulin and insulin like growth factor (IGF) signaling systems are implicated in breast cancer biology. Thus, disrupting IGF/insulin signaling has been shown to have promise in a number of preclinical models. However, human clinical trials have been less promising. Despite evidence of some activity in early phase trials, randomized phase III studies have thus far been unable to show a benefit of blocking IGF signaling in combination with conventional strategies. In breast cancer, combination anti IGF/insulin signaling agents with hormone therapy has not yet proven to have benefit. This inability to translate the preclinical findings into useful clinical strategies calls attention to the need for a deeper understanding of this complex pathway. Development of predictive biomarkers and optimal inhibitory strategies of the IGF/insulin system should yield better clinical strategies. Furthermore, unraveling the interaction between the IGF/insulin pathway and other critical signaling pathways in breast cancer biology, namely estrogen receptor-α (ERα) and epidermal growth factor receptor (EGFR) pathways, provides additional new concepts in designing combination therapies. In this review, we will briefly summarize the current strategies targeting the IGF/insulin system, discuss the possible reasons of success or failure of the existing therapies, and provide potential future directions for research and clinical trials.
      datePublished:2012-10-10T00:00:00Z
      dateModified:2012-10-10T00:00:00Z
      pageStart:251
      pageEnd:261
      sameAs:https://doi.org/10.1007/s10911-012-9268-y
      keywords:
         Breast cancer
         Insulin-like growth factor
         Type I receptor IGF receptor
         Insulin receptor
         Predictive biomarkers
         Oncology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10911-012-9268-y/MediaObjects/10911_2012_9268_Fig1_HTML.gif
      isPartOf:
         name:Journal of Mammary Gland Biology and Neoplasia
         issn:
            1573-7039
            1083-3021
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yuzhe Yang
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Minnesota
                  address:
                     name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas Yee
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Department of Medicine, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Minnesota
                  address:
                     name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Mammary Gland Biology and Neoplasia
      issn:
         1573-7039
         1083-3021
      volumeNumber:17
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Minnesota
      address:
         name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Department of Medicine, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yuzhe Yang
      affiliation:
            name:University of Minnesota
            address:
               name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
            name:University of Minnesota
            address:
               name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Douglas Yee
      affiliation:
            name:University of Minnesota
            address:
               name:Department of Medicine, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
            name:University of Minnesota
            address:
               name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
      name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
      name:Department of Medicine, University of Minnesota, Minneapolis, USA
      name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(284)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.17s.